Literature DB >> 21596773

Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important?

Yaroslau Compta1,2, Laura Parkkinen1, Sean S O'Sullivan1, Jana Vandrovcova3, Janice L Holton1, Catherine Collins3, Tammaryn Lashley1, Constantinos Kallis4, David R Williams1,5, Rohan de Silva3, Andrew J Lees1,3, Tamas Revesz1.   

Abstract

The relative importance of Lewy- and Alzheimer-type pathologies to dementia in Parkinson's disease remains unclear. We have examined the combined associations of α-synuclein, tau and amyloid-β accumulation in 56 pathologically confirmed Parkinson's disease cases, 29 of whom had developed dementia. Cortical and subcortical amyloid-β scores were obtained, while tau and α-synuclein pathologies were rated according to the respective Braak stages. Additionally, cortical Lewy body and Lewy neurite scores were determined and Lewy body densities were generated using morphometry. Non-parametric statistics, together with regression models, receiver-operating characteristic curves and survival analyses were applied. Cortical and striatal amyloid-β scores, Braak tau stages, cortical Lewy body, Lewy neurite scores and Lewy body densities, but not Braak α-synuclein stages, were all significantly greater in the Parkinson's disease-dementia group (P<0.05), with all the pathologies showing a significant positive correlation to each other (P<0.05). A combination of pathologies [area under the receiver-operating characteristic curve=0.95 (0.88-1.00); P<0.0001] was a better predictor of dementia than the severity of any single pathology. Additionally, cortical amyloid-β scores (r=-0.62; P=0.043) and Braak tau stages (r=-0.52; P=0.028), but not Lewy body scores (r=-0.25; P=0.41) or Braak α-synuclein stages (r=-0.44; P=0.13), significantly correlated with mini-mental state examination scores in the subset of cases with this information available within the last year of life (n=15). High cortical amyloid-β score (P=0.017) along with an older age at onset (P=0.001) were associated with a shorter time-to-dementia period. A combination of Lewy- and Alzheimer-type pathologies is a robust pathological correlate of dementia in Parkinson's disease, with quantitative and semi-quantitative assessment of Lewy pathology being more informative than Braak α-synuclein stages. Cortical amyloid-β and age at disease onset seem to determine the rate to dementia.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21596773      PMCID: PMC4194668          DOI: 10.1093/brain/awr031

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  52 in total

1.  Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease.

Authors:  H I Hurtig; J Q Trojanowski; J Galvin; D Ewbank; M L Schmidt; V M Lee; C M Clark; G Glosser; M B Stern; S M Gollomp; S E Arnold
Journal:  Neurology       Date:  2000-05-23       Impact factor: 9.910

2.  Staging of brain pathology related to sporadic Parkinson's disease.

Authors:  Heiko Braak; Kelly Del Tredici; Udo Rüb; Rob A I de Vos; Ernst N H Jansen Steur; Eva Braak
Journal:  Neurobiol Aging       Date:  2003 Mar-Apr       Impact factor: 4.673

3.  Relationships between age and late progression of Parkinson's disease: a clinico-pathological study.

Authors:  Peter A Kempster; Sean S O'Sullivan; Janice L Holton; Tamas Revesz; Andrew J Lees
Journal:  Brain       Date:  2010-04-05       Impact factor: 13.501

4.  Striatal beta-amyloid deposition in Parkinson disease with dementia.

Authors:  Michail E Kalaitzakis; Manuel B Graeber; Stephen M Gentleman; Ronald K B Pearce
Journal:  J Neuropathol Exp Neurol       Date:  2008-02       Impact factor: 3.685

5.  Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI.

Authors:  J E Hixson; D T Vernier
Journal:  J Lipid Res       Date:  1990-03       Impact factor: 5.922

6.  Alpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson's disease.

Authors:  P M Mattila; J O Rinne; H Helenius; D W Dickson; M Röyttä
Journal:  Acta Neuropathol       Date:  2000-09       Impact factor: 17.088

7.  Alzheimer beta amyloid deposition enhanced by apoE epsilon4 gene precedes neurofibrillary pathology in the frontal association cortex of nondemented senior subjects.

Authors:  H Yamaguchi; S Sugihara; A Ogawa; N Oshima; Y Ihara
Journal:  J Neuropathol Exp Neurol       Date:  2001-07       Impact factor: 3.685

Review 8.  Neuropathology of non-motor features of Parkinson disease.

Authors:  Dennis W Dickson; Hiroshige Fujishiro; Carolyn Orr; Anthony DelleDonne; Keith A Josephs; Roberta Frigerio; Melinda Burnett; Joseph E Parisi; Kevin J Klos; J Eric Ahlskog
Journal:  Parkinsonism Relat Disord       Date:  2009-12       Impact factor: 4.891

9.  The effect of age of onset of PD on risk of dementia.

Authors:  D Aarsland; J T Kvaløy; K Andersen; J P Larsen; M X Tang; A Lolk; P Kragh-Sørensen; K Marder
Journal:  J Neurol       Date:  2007-02-14       Impact factor: 4.849

10.  Neuropathology of Parkinson's disease dementia and dementia with Lewy bodies with reference to striatal pathology.

Authors:  Yoshio Tsuboi; Hirotake Uchikado; Dennis W Dickson
Journal:  Parkinsonism Relat Disord       Date:  2007       Impact factor: 4.891

View more
  195 in total

Review 1.  CSF and clinical hallmarks of subcortical dementias: focus on DLB and PDD.

Authors:  Alessandro Stefani; Livia Brusa; Enrica Olivola; Mariangela Pierantozzi; Alessandro Martorana
Journal:  J Neural Transm (Vienna)       Date:  2012-05-24       Impact factor: 3.575

2.  An update on brain imaging in parkinsonian dementia.

Authors:  Myria Petrou; Vikas Kotagal; Nicolaas I Bohnen
Journal:  Imaging Med       Date:  2012-04

Review 3.  The Therapeutic Potential of Exercise to Improve Mood, Cognition, and Sleep in Parkinson's Disease.

Authors:  Gretchen O Reynolds; Michael W Otto; Terry D Ellis; Alice Cronin-Golomb
Journal:  Mov Disord       Date:  2015-12-30       Impact factor: 10.338

4.  Neuropathologic substrates of Parkinson disease dementia.

Authors:  David J Irwin; Matthew T White; Jon B Toledo; Sharon X Xie; John L Robinson; Vivianna Van Deerlin; Virginia M-Y Lee; James B Leverenz; Thomas J Montine; John E Duda; Howard I Hurtig; John Q Trojanowski
Journal:  Ann Neurol       Date:  2012-10-04       Impact factor: 10.422

Review 5.  The neurobiology and neural circuitry of cognitive changes in Parkinson's disease revealed by functional neuroimaging.

Authors:  Nicola J Ray; Antonio P Strafella
Journal:  Mov Disord       Date:  2012-10-04       Impact factor: 10.338

6.  Striatal and Cortical β-Amyloidopathy and Cognition in Parkinson's Disease.

Authors:  Neha Shah; Kirk A Frey; Martijn L T M Müller; Myria Petrou; Vikas Kotagal; Robert A Koeppe; Peter J H Scott; Roger L Albin; Nicolaas I Bohnen
Journal:  Mov Disord       Date:  2015-09-18       Impact factor: 10.338

Review 7.  Challenges of multimorbidity of the aging brain: a critical update.

Authors:  Kurt A Jellinger; Johannes Attems
Journal:  J Neural Transm (Vienna)       Date:  2014-08-05       Impact factor: 3.575

Review 8.  Mesencephalic and extramesencephalic dopaminergic systems in Parkinson's disease.

Authors:  Fanni F Geibl; Martin T Henrich; Wolfgang H Oertel
Journal:  J Neural Transm (Vienna)       Date:  2019-01-14       Impact factor: 3.575

9.  Prognosis and Neuropathologic Correlation of Clinical Subtypes of Parkinson Disease.

Authors:  Eduardo De Pablo-Fernández; Andrew J Lees; Janice L Holton; Thomas T Warner
Journal:  JAMA Neurol       Date:  2019-04-01       Impact factor: 18.302

10.  Prominent psychiatric symptoms in patients with Parkinson's disease and concomitant argyrophilic grain disease.

Authors:  O Grau-Rivera; E Gelpi; M J Rey; F Valldeoriola; E Tolosa; Y Compta; M J Martí
Journal:  J Neurol       Date:  2013-09-18       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.